PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-1.48%
Negative EBIT growth while RVPH is at 5.85%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
3.86%
Operating income growth at 50-75% of RVPH's 7.11%. Martin Whitman would doubt the firm’s ability to compete efficiently.
-1.47%
Negative net income growth while RVPH stands at 5.90%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
12.77%
EPS growth above 1.5x RVPH's 7.69%. David Dodd would review if superior product economics or effective buybacks drive the outperformance.
13.49%
Diluted EPS growth above 1.5x RVPH's 7.69%. David Dodd would see if there's a robust moat protecting these shareholder gains.
16.41%
Share count expansion well above RVPH's 2.47%. Michael Burry would question if management is raising capital unnecessarily or is over-incentivizing employees with stock.
17.29%
Diluted share count expanding well above RVPH's 2.47%. Michael Burry would fear significant dilution to existing owners' stakes.
No Data
No Data available this quarter, please select a different quarter.
23.86%
OCF growth at 50-75% of RVPH's 38.83%. Martin Whitman would question if the firm lags in monetizing sales effectively.
23.57%
FCF growth 50-75% of RVPH's 38.83%. Martin Whitman would see if structural disadvantages exist in generating free cash.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21198.65%
Negative 10Y OCF/share CAGR while RVPH stands at 0.00%. Joel Greenblatt would scrutinize managerial effectiveness and product competitiveness.
-19211.55%
Negative 5Y OCF/share CAGR while RVPH is at 21.52%. Joel Greenblatt would question the firm’s operational model or cost structure.
-43.46%
Negative 3Y OCF/share CAGR while RVPH stands at 53.59%. Joel Greenblatt would demand an urgent turnaround in the firm’s cost or revenue drivers.
-15978.83%
Both face negative decade-long net income/share CAGR. Martin Whitman would suspect a shrinking or highly disrupted sector.
-50766.69%
Negative 5Y net income/share CAGR while RVPH is 60.51%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
48.21%
3Y net income/share CAGR 75-90% of RVPH's 58.01%. Bill Ackman might push for an operational plan to match or beat the competitor’s short-term growth.
19776.75%
Equity/share CAGR of 19776.75% while RVPH is zero. Bruce Berkowitz might see a slight advantage that can compound significantly over 10 years.
4394.26%
Equity/share CAGR of 4394.26% while RVPH is zero. Bruce Berkowitz might see a minor advantage that could compound if the firm maintains positive net worth growth.
625.15%
Positive short-term equity growth while RVPH is negative. John Neff sees a strong advantage in near-term net worth buildup.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
30.51%
Asset growth well under 50% of RVPH's 64.40%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.
8.68%
Under 50% of RVPH's 89.95%. Michael Burry raises concerns about the firm’s ability to build intrinsic value relative to its rival.
No Data
No Data available this quarter, please select a different quarter.
-31.37%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
108.24%
We expand SG&A while RVPH cuts. John Neff might see the competitor as more cost-optimized unless we expect big payoffs from the overhead growth.